Longeveron Inc. LGVN
We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B®.
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. Laromestrocel possesses broad potential applications across a spectrum of disease areas. Our mission is to continue to advance the development and regulatory approval of laromestrocel in order to make it available for patients who may need it.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $2.4M | $709.0K | $1.2M | $708.0K | $55.0K | — |
| Cost of revenue | $396.0K | $508.0K | $488.0K | $725.0K | $716.0K | $3.8M | — |
| Gross profit | $803.0K | $1.9M | $221.0K | $497.0K | $590.0K | $1.8M | — |
| R&D | $12.0M | $8.1M | $9.1M | $9.4M | $7.1M | $2.7M | — |
| SG&A | $12.0M | $10.3M | $12.2M | $8.1M | $9.7M | $2.7M | — |
| Total operating expenses | $24.1M | $18.4M | $21.2M | $18.5M | $18.0M | $5.6M | — |
| Operating income | -$23.3M | -$16.5M | -$21.0M | -$18.0M | -$17.5M | -$3.8M | — |
| Interest expense | — | — | — | $1.4M | — | — | — |
| Pre-tax income | -$22.7M | -$16.0M | -$21.4M | -$18.8M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | — | — | — |
| Net income | -$22.7M | -$16.0M | -$21.4M | -$18.8M | -$17.0M | -$3.7M | — |
| EPS, basic | -1.29 | -2.62 | -10.22 | -0.90 | -0.90 | — | — |
| EPS, diluted | -1.29 | -2.62 | -10.22 | -0.90 | -0.90 | -0.23 | — |
| Shares, diluted (wtd. avg.) | $17.58B | $9.41B | $2.17B | $21.0M | $18.9M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.7M | $19.2M | $4.9M | $10.5M | $25.7M | $816.0K | $1.9M |
| Short-term investments | — | $0 | $412.0K | $9.2M | $9.5M | — | — |
| Receivables | $104.0K | $84.0K | $111.0K | $218.0K | $55.0K | — | — |
| Total current assets | $5.5M | $19.6M | $5.8M | $20.3M | $35.4M | $1.8M | — |
| Property, plant and equipment | $1.8M | $2.4M | $2.5M | $2.9M | $3.1M | $3.6M | — |
| Other intangibles | $2.3M | $2.4M | $2.3M | $2.4M | $2.3M | $1.5M | — |
| Total assets | $10.3M | $25.6M | $12.1M | $27.4M | $42.8M | $9.2M | — |
| Accounts payable | $423.0K | $99.0K | $638.0K | $1.8M | $645.0K | $1.6M | — |
| Total current liabilities | $4.1M | $2.6M | $3.9M | $4.9M | $2.7M | $3.8M | — |
| Long-term debt | — | — | — | — | — | $311.0K | — |
| Total liabilities | $4.6M | $3.7M | $5.3M | $6.9M | $5.3M | $7.3M | — |
| Retained earnings | -$132.3M | -$109.6M | -$85.0M | -$62.8M | -$43.9M | — | — |
| Total equity | $5.7M | $21.9M | $6.7M | $20.5M | $37.5M | $2.0M | $4.4K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.6M | -$13.9M | -$19.0M | -$14.0M | -$9.6M | -$2.4M | — |
| Depreciation and amortisation | $800.0K | $700.0K | $700.0K | $700.0K | $1 | $1 | — |
| Stock-based compensation | $1.7M | $2.3M | $2.0M | $2.2M | $1.3M | $44.0K | — |
| Capital expenditure | $245.0K | $655.0K | $301.0K | $569.0K | $330.0K | $131.0K | — |
| Investing cash flow | -$595.0K | -$640.0K | $8.2M | -$677.0K | -$10.7M | -$261.0K | — |
| Financing cash flow | $4.7M | $28.8M | $5.3M | -$509.0K | $45.2M | $1.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-110664.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |